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Abstract
For people with chronic autoimmune rheumatic diseases (AIRD), such as rheumatoid arthritis (RA), systemic lupus
erythematosus (SLE) or systemic sclerosis (SSc), normal cognitive functions are essential for performing daily
activities. These diseases may be associated with cognitive dysfunction (CD). In RA, CD has been associated with
age, lower education and disease duration and activity. Great advances have been achieved in neuropsychiatric SLE
in the identification of pathogenic pathways, assessment and possible treatment strategies. SSc rarely exerts direct
effects on the brain and cognitive function. However, the psychological burden that includes depression, anxiety
and social impact may be high. AIRD patients with sustained disease activity, organ damage or lower education
should be evaluated for CD. The control of systemic inflammation together with tailored behavioural cognitive
therapies may benefit these patients.
Keywords: Cognitive function, Cognitive dysfunction, Rheumatoid arthritis, Systemic lupus erythematosus,
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Introduction
Cognitive function includes orientation, attention/concen-
tration, judgment/problem solving and memory, verbal, vis-
ual/spatial and executive functions [1]. Several standardised
measures of cognitive function have been developed. These
include the Montreal Cognitive Assessment (MoCA), Trail
Making Test (TMT), Victoria Stroop Test (VST), Wechsler
Adult Intelligence Scale (WAIS) and Benton Visual Reten-
tion Test (BVRT). Beck Depression Inventory (BDI) and
State-Trait Anxiety Inventory (STAIT/S) may be used to
assess depression and anxiety, respectively [2]. For people
with chronic illnesses, such as autoimmune-inflammatory
rheumatic diseases (AIRD), intact cognitive functioning is
crucial for performing many key daily tasks, including
medical treatment adherence or planning activities. Most
AIRDs have been associated with various degrees of
cognitive dysfunction (CD) (reviewed in [1, 3, 4]). In this re-
view, we will briefly discuss CD in rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE) and systemic
sclerosis (SSc).
Rheumatoid arthritis
Introduction
RA exerts various neuropsychiatric manifestations [5].
There is an increased risk of stroke, a consequence of
accelerated inflammatory atherosclerosis, especially in
elderly RA patients with a long-standing disease [5].
Among psychiatric manifestations, depression and anx-
iety are present in two thirds of RA patients and have
been associated with disease activity [6].
In RA, patients may significantly underperform on
cognitive function tests compared to controls [1, 2, 7].
Even mild CD may influence the functional capacity and
quality of life of these patients [1, 7, 8]. It affects reactiv-
ity to pain, compliance to and effectiveness of therapy
[1]. This CD may occur early, in young RA patients,
even in the early stages of the disease [9]. In general, CD
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may influence daily activities, treatment compliance and
overall self-care [1, 2]. Meade et al. [1] have recently per-
formed the first systematic review of CD in RA.
Pathogenesis
Both inflammation itself that also affects the brain [1, 8]
and accelerated atherosclerosis also driven by systemic
inflammation including pro-inflammatory cytokines [10]
may cause CD in RA. RA disease activity associated with
systemic inflammation may be an important driver of
CD, as well as depression and anxiety [1, 8]. Clinical fea-
tures, such as pain, stress, fatigue and sleep disturbances,
may be involved in the development of RA-associated
CD. For example, depression can lead to abnormal con-
centration and executive function [1, 11]. Among anti-
rheumatic drugs, methotrexate (MTX) and corticoste-
roids have been associated with CD. The effects of these
compounds on RA-related CD may be controversial.
Both MTX and corticosteroids dampen systemic inflam-
mation and thus may have beneficial effects on cognitive
function. On the other hand, MTX has been associated
with CD, mood changes and confusion, while corticoste-
roids may have an impact on memory and hippocampal
function [1, 12].
Assessment tools
We have recently applied numerous standard validated
measures in order to assess cognitive function, depres-
sion and anxiety in RA patients in association with the
assessment of cerebral circulation and pathology by
transcranial Doppler (TCD), carotid ultrasound and
brain MRI [2]. Standard measures of CD including MoCA,
TMT, VST, WAIS and BVRT, as well as BDI and STAI
measuring depression and anxiety, showed impairment in
RA vs controls. Biologic- vs MTX-treated subgroups also
showed some difference in a few measures [2]. Shin et al.
[7] used 16 cognitive indices and found a relationship be-
tween cognitive and functional limitations. We have re-
ported the impairment of most mental domains in the SF-
36 quality of life assessment tool in RA [2]. In our study,
numerous cognitive tests correlated with age and lower
education. Some also correlated with disease duration,
ESR and disease activity [2]. Shin et al. [7] and Lee et al.
[13] also associated CD with low education and disease
activity, respectively. Regarding vascular pathophysiology,
cerebral vascular lesions, TCD parameters and carotid pla-
ques were associated with impairment of multiple cogni-
tive parameters [2].
Management
The control of disease activity may be essential in this
respect [1, 8]. Although preliminary studies suggested
that MTX may aggravate CD, the beneficial effects of
MTX and biologics on the suppression of disease activity
may override this potential effect [1]. Although pro-
inflammatory mediators have been implicated in the de-
velopment of CD in RA [1, 8], only very few studies evalu-
ated the longitudinal effects of anti-rheumatic drugs on
cognitive function. In the open-label study of Raftery et al.
[14], adalimumab improved full scale, verbal and perform-
ance IQ in parallel with improvements of DAS28. Camara
et al. [15] reported that centrally administered etanercept
improved anxiety-like behaviour in mice. In addition to
pharmacotherapy, tailored cognitive-behavioural therapy
(CBT) administered early in the course of RA also reduced
health care use for the first 5 years after treatment [16].
Systemic lupus erythematosus
Introduction
Neuropsychiatric manifestations in SLE, formerly known
as lupus cerebritis, are diverse and common. An Ameri-
can College of Rheumatology (ACR) ad hoc committee
in 1999 described 19 neuropsychiatric syndromes that
can be directly attributed to SLE, ranging from stroke,
acute confusional state and transverse myelitis to more
low-grade, non-specific symptoms such as headaches,
mood disorders and cognitive impairment [17]. While
often considered subtle and non-specific, lupus patients
have identified CD as one of the most distressing symp-
toms of their disease. Studies have estimated that CD af-
fects 3–81% of lupus patients [3], the wide range
resulting from non-standardised diagnostic criteria and
screening tools, and difficulty in the attribution of symp-
toms to SLE. Additional hurdles in the diagnosis of neuro-
psychiatric manifestations are that they often develop
insidiously, can present and progress independently of
other signs of SLE activity and often do not respond to
standard immunosuppression. Thus, there is growing rec-
ognition that CD in lupus patients remains underdiag-
nosed and under-addressed in the clinical setting [18].
Pathogenesis
Suffering from a chronic disease state, taking neurotoxic/
psychoactive medications such as corticosteroids and cyclo-
phosphamide, and other manifestations of neuropsychiatric
SLE (NPSLE) such as strokes, seizures, depression or anx-
iety can all independently lead to CD. Nevertheless, the
early presentation of neuropsychiatric symptoms (40% of
lupus patients suffer from neuropsychiatric symptoms on
presentation or within the first 3 years of disease diagnosis
[19, 20]), the increased prevalence of CD in lupus patients
compared to other chronic inflammatory diseases [3],
in addition to animal models displaying associated be-
haviours [21], strongly points to a disease-specific, im-
munologic aetiology. Pathogenic pathways thought to
be instrumental in NPSLE have been comprehensively
described elsewhere [21], but here, we will briefly
discuss those that have been specifically linked to
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cognitive dysfunction. Antiphospholipid (aPL) anti-
bodies, often associated with SLE and known to be a
strong risk factor for NPSLE, lead to a hypercoagula-
ble state often resulting in strokes, structural damage
and associated CD [21, 22]. Of note, aPL antibodies
have also been linked to less clearly understood
NPSLE syndromes that are not necessarily directly re-
lated to thrombosis or ischaemic events [23]. In fact,
there is evidence for the involvement of multiple as-
pects of the immune system in NPSLE, including
neurotoxic autoantibodies, pro-inflammatory cyto-
kines and cell-mediated effects, in conjunction with
abnormalities in neuroimmune interfaces including
the choroid plexus and blood-brain barrier which
allow systemic autoimmune drivers into the central
nervous system [21, 24]. Specifically, several studies
have pointed to increased systemic levels of cytokines
such as interleukin 6 (IL-6) and neurotoxic anti-N-me-
thyl-D-aspartate receptor (NMDAR) antibodies in SLE
patients with CD [25–27]. In addition, type I inter-
feron (IFN-I) and anti-NMDAR antibodies were
shown to enhance microglia activation, leading to ab-
errant synaptic pruning with subsequent CD [28, 29].
There is some experimental evidence to suggest that
microglia activation can be dampened with both anti-
IFN-α/β receptor (IFNAR) treatment and the blood-
brain barrier-crossing angiotensin-converting enzyme
(ACE) inhibitor captopril. These interventions were
associated with improvement in neurobehavioural def-
icits in lupus mice [28, 29], although there was a con-
flicting report with anti-IFNAR treatment and its
effect on neuropsychiatric symptoms [30].
While promising directions in terms of investigations
into the pathogenesis, as well as specific treatments of
CD, are starting to accrue, those are still mainly focused
on animal disease models, limiting our ability to ex-
trapolate these findings to human disease [21, 28–30].
Measurement tools
The ACR 1999 nomenclature defined CD as including a
significant deficit in any or all of the following cognitive
domains: simple or complex attention, reasoning, execu-
tive skills, memory, visual-spatial processing, language
and psychomotor speed [17]. Among these, in SLE,
language and working memory domains are most
commonly affected, followed by simple attention and
psychomotor speed [3]. Rayes et al. [3] presented a com-
prehensive meta-analysis evaluating different neurocog-
nitive testing tools used to assess CD in SLE. While the
4-h, complete battery of neurocognitive testing is the
most comprehensive, it is not feasible for routine assess-
ments of patients in the clinical setting. A number of al-
ternative modalities have been utilised with varying
degrees of agreements with the complete neurocognitive
testing battery, including the ACR-SLE battery [17], a 1-
h battery of tests that focus on SLE-specific domains
that show good agreement with the complete battery in
healthy controls and SLE patients without NPSLE (96%
and 95% agreement, respectively, with 100% sensitivity
in both groups, and 96% specificity in controls and 94%
in SLE without NPSLE), but only moderate agreement in
patients with NPSLE (81% agreement, with 80% sensitiv-
ity and 81% specificity) [31]. While the ACR-SLE battery
has been shown to be a relatively good CD evaluating
tool in SLE patients, its main barrier is the significant
time and resources it requires for administration, mak-
ing it challenging for routine use. The Automated
Neuropsychological Assessment Metric (ANAM) is a
40-min, self-administered computerised test that has
been validated in multi-ethnic populations and is less in-
fluenced by age, education, English language proficiency
and depression than other forms of neurocognitive test-
ing [32, 33]. When compared to the ACR-SLE battery,
the ANAM was found to have a sensitivity of 78–80%
and specificity of 70% [32, 33], demonstrating promise
as a possible CD screening method. The ANAM, how-
ever, needs further analysis of its capacity to monitor
changes in CD over time and is thought to lack the abil-
ity to identify specific domain impairments [3]. Finally,
the MoCA test, already mentioned above, is a brief, 15-
min administered test that showed acceptable agreement
with the ANAM (sensitivity 83% and specificity 73%) but
requires more extensive validation prior to clinical and
investigational use [34]. Identifying and validating a reli-
able screening and monitoring tool for CD that is both
sensitive and specific, as well as technically feasible in
the clinical setting, are of the utmost importance. Rely-
ing on patients’ self-reporting is clearly inadequate, espe-
cially as studies comparing patient self-reporting to
objective findings of CD found no association between
the two, most probably because self-perception of CD is
often closely associated with depression and anxiety
[35]. It is also important to emphasise that these tests
may be useful for the identification and quantification of
CD, but are not specific for NPSLE, and do not allow
the discerning of primary SLE-related CD from any
other confounding causes.
Advanced imaging studies
The pathways underlying lupus CD are still being ex-
plored, and the currently available diagnostic tools are
not specific and/or have yet to be fully validated and
broadly accepted. Thus, there remains a need for an ob-
jective and non-invasive means to establish neurological
dysfunction in SLE patients both for investigative pur-
poses, as well as for clinical diagnosis and surveillance.
There is evidence to suggest that SLE patients, with and
without overt NPSLE, have aberrations in their white
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matter microstructures as seen by diffusion tensor im-
aging (DTI) [36]. Functional MRI studies have shown in-
creased functional connectivity in core resting-state
networks in SLE patients that correlate with reduced
cognitive performance compared with healthy controls
[37]. FDG-PET imaging highlighted hypermetabolic re-
gions that corresponded with increased serum anti-
NMDAR antibodies in SLE patients with CD and did
not correlate with disease duration, activity, medications
or comorbidities [26, 27]. These studies highlight a po-
tential role for these imaging techniques in objectively
diagnosing and monitoring CD in SLE patients.
Attribution of CD to SLE
The potential use of imaging studies to diagnose CD in
SLE in an unbiased and disease-specific setting is appeal-
ing, especially as there are numerous confounders that
can affect CD in SLE patients. As we noted, mood disor-
ders, depression, chronic pain, corticosteroid use and
struggling with a chronic illness from a young age are all
known to contribute to CD and are quite common in
SLE patients. In order to better study, address and man-
age CD symptoms in SLE patients, it is important to first
be able to correctly attribute them to the disease itself.
To that end, several models have been devised to aid cli-
nicians in attributing the symptoms to SLE (comprehen-
sively reviewed in [38]). These models take into account
factors such as the temporal relationship between the
onset of neuropsychiatric symptoms and diagnosis or
change in the activity of SLE, viable alternative explana-
tions and the presence of risk factors specific to SLE
such as aPL antibodies [22]. However, these models have
been developed with the expert opinion being the diag-
nostic gold standard, with no objective corroborating
evidence. Therefore, the attribution of CD to SLE re-
mains mainly reliant on the clinician’s assessment, index
of suspicion and clinical reasoning, which can benefit
from the introduction of a collaborative multidisciplinary
approach including neuropsychological, radiological and
laboratory evaluations [21, 39].
Systemic sclerosis
Introduction
Scleroderma encompasses several significant immune-
mediated diseases that lead to thickening or fibrosis of
the skin. The most severe forms medically are those in
which systemic involvement occurs, namely SSc [40]. It
has been suggested that the central nervous system is
one of the very few organs that is not involved in SSc,
but in fact, there are several aspects of the disease where
cognitive function is clearly relevant and important. The
localised forms of scleroderma, termed morphoea, are
also important in terms of functional and cosmetic bur-
den due to their impact on local connective tissue
growth and appearance. Interestingly emotional stress is
recognised as a factor in the development of scleroderma,
and it is not uncommon for patients to describe major
emotional difficulties such as bereavement or divorce in
the 12–18months prior to disease onset [41]. In this way,
the interplay between the neurocognitive processes and
immune or inflammatory disease is highlighted.
Psychological burden in SSc
More specific issues occur due to the impact of SSc on
physical appearance and function. This can impact on
almost all aspects of daily life and has a major detrimen-
tal effect on social interaction. Reasons for this include
the effect on appearance as well as difficulties related to
eating, working or participating in normal sociable activ-
ities. The impact is clear from studies that have used val-
idated instruments to assess burden [42]. In addition,
there has been a clear demonstration that clinical inter-
ventions that can improve facial appearance, such as au-
tologous fat transfer, can greatly improve the score of
psychological well-being [43].
There have been recent attempts to better describe
and quantify psychological burden in SSc, and these
have used the randomised cohort design of the SPIN
project [44]. This approach allows greater evidence gath-
ering to assess the utility of measurement tools as well
as possible intervention strategies [45]. This is important
because the psychological impact of SSc is frequently
highlighted by patients as a major unmet need and one
that is not well addressed in current approaches to treat-
ment [44, 45]. The shared aspects across other immune-
mediated or chronic diseases may be important in plan-
ning future interventions.
Cognitive impairment in SSc
In general, although anxiety, depression and mood diffi-
culties are common, CD in SSc is not a frequent compli-
cation of the disease process. This contrasts with other
AIRDs and might reflect fundamental differences in the
cytokine or other immune cell drives across diseases
[46]. There are however instances where vascular dam-
age can be relevant. The most striking example is in the
context of scleroderma renal crisis. This is a form of
thrombotic microangiopathy associated with accelerated
phase hypertension that occurs almost exclusively in
early-stage diffuse cutaneous SSc and is strongly associ-
ated with the anti-RNA polymerase autoantibodies. There
is a propensity to end-organ damage that may reflect the
systemic microvasculopathy of SSc and may lead to gener-
alised seizures and on occasion significant CD [47]. Fortu-
nately, this generally recovers over several weeks without
sequelae. A recent study formally assessed cognitive func-
tion in a cohort of SSc cases found evidence of cognitive
impairment compared with matched healthy controls and
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that this associated with worse vascular disease. Future
studies may explore whether this relates to comorbidity or
is a specific feature of SSc [48].
Approximately one in five patients with SSc will also
manifest additional features of another AIRD, such as
SLE or Sjögren’s syndrome [49]. This is important be-
cause the cognitive impact of these other diseases will be
an additional burden for patients and may sometimes be
the predominant problem, as outlined in other parts of
this article. Immune-mediated encephalitic states may
occur occasionally in this context [50].
Finally, it is notable that SSc is associated with Ray-
naud’s phenomenon, and there have been several re-
ports of mental or cognitive impact of cold exposure
[4]. This has in some cases been associated with
changes in cerebral perfusion scan and raises the in-
triguing possibility that Raynaud’s might on occasion
affect the cerebral circulation [4]. This has not been
definitely shown, and more research is needed. Like-
wise, in localised scleroderma, especially linear mor-
phoea, there can be structural abnormalities affecting
the cranium or brain substance. This has been associ-
ated with epilepsy and possibly also with cognitive
complications in some cases.
Conclusion
Patients with RA, SLE or SSc may exert significant
cognitive impairment. In RA, various domains of cog-
nitive dysfunction may be associated with age, lower
education, disease duration and activity, inflammatory
markers and some measures of vascular pathology.
Important strides have been made in NPSLE- and
SLE-specific CD in particular, in the elucidation of
the pathogenic pathways and possible treatment strat-
egies, imaging studies, and the design and validation
of clinically feasible and diagnostically acceptable
screening and monitoring tools. SSc rarely directly af-
fects brain function, but the psychological burden can
be large including depression anxiety and social im-
pact. This represents a major unmet need that will
likely remain a key problem despite promising data
from ongoing and recent clinical trials of potential
therapies for skin or lung manifestations of the dis-
ease. Although there have been fewer studies of cog-
nitive impairment in SSc that for SLE or RA, it is
important and maybe addressed in future work, per-
haps utilising the randomised cohort design of the
SPIN consortium [44]. From the practical point of
view, AIRD patients, especially those with higher age,
lower education, sustained disease activity and higher
damage indices, should be evaluated for CD by any
standard test. Although some anti-rheumatic agents
may impair cognitive function, the control of inflam-
mation by conventional and biologic DMARDs, in
association with tailored behavioural cognitive therap-
ies, may benefit our AIRD patients. There obviously
is still much work to be done in developing the right
tools to best serve and optimally manage these pa-
tients with this distressing complication of an already
challenging disease.
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